Vineet Laboratories Limited , a pharmaceutical company, has reported significant changes in its promoter shareholdings through two separate transactions.

Mrs. Gaddam Venkata Rama's Transaction

Mrs. Gaddam Venkata Rama, a promoter of the company, executed a sale of 1,50,000 equity shares through the National Stock Exchange (NSE). The transaction was valued at ₹50.10 lakh, implying an average price of approximately ₹33.40 per share.

Impact on Shareholding

The sale has resulted in a notable reduction in Mrs. Gaddam's stake in the company:

This transaction represents a decrease of 1.63 percentage points in Mrs. Gaddam's ownership of the company.

Mr. Satyanarayana Raju Bhupathiraju's Transaction

In a separate transaction, Mr. Satyanarayana Raju Bhupathiraju, another promoter, sold 56,164 equity shares. Following the sale, his shareholding decreased from 406,452 shares (3.50%) to 350,288 shares (3.02%).

Regulatory Compliance

Both sales were conducted on the open market and have been disclosed in accordance with the Securities and Exchange Board of India (SEBI) Insider Trading Regulations. Vineet Laboratories Limited has duly informed the stock exchanges about these transactions, as required by Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015.

Company Response

Ramesh Kumar Bandari, the Company Secretary and Compliance Officer of Vineet Laboratories Limited, has confirmed the receipt of the intimations from both promoters regarding their respective share sales. The company has promptly disclosed this information to both the BSE Limited and the National Stock Exchange of India Limited.

Investors and market participants are advised to take note of these changes in the promoter shareholding pattern of Vineet Laboratories Limited. Such transactions often attract attention as they may influence market sentiment and perceptions about the company's future prospects.

Vineet Laboratories Limited, a pharmaceutical company, has announced significant corporate actions that require shareholder approval through a postal ballot. The company's Board of Directors met on August 12, 2025, to approve these proposals, which include increasing the authorized share capital and appointing a new non-executive director.

Key Proposals

1. Increase in Authorized Share Capital: The board has proposed an increase in the company's authorized share capital. This move would necessitate changes to Clause V of the Memorandum of Association.

2. Raising Financial Thresholds: The company seeks to increase the thresholds for loans, guarantees, securities, and investments. This could potentially provide Vineet Laboratories with greater financial flexibility.

3. New Director Appointment: Mr. Premananda Reddy Vennapusa has been proposed for appointment as a Non-Executive Director, in accordance with Section 160 of the Companies Act, 2013.

Voting Details

Regulatory Compliance

The company has informed both the BSE Limited and the National Stock Exchange of India Limited about these developments, in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Vineet Laboratories Limited is taking these steps as part of its corporate strategy. Shareholders will play a crucial role in deciding the outcome of these proposals through the upcoming postal ballot.

The management's decision to seek shareholder approval for these significant changes underscores the company's commitment to corporate governance and transparency. Investors and market watchers will be keenly observing the results of this postal ballot, as the outcomes could have implications for the company's future growth and financial strategies.